Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


Exagen to Announce Second Quarter Financial Results on July 28, 2020


GlobeNewswire Inc | Jul 16, 2020 10:46AM EDT

July 16, 2020

SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that it will release financial results for the quarter ended June 30, 2020 before the market opens on Tuesday, July 28, 2020. Ron Rocca, President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Companys results at 8:00 AM Eastern Time (5:00 AM Pacific Time).

Interested parties may access the conference call by dialing (877) 407-3982 (U.S.) or (201) 493-6780 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at https://investors.exagen.com/

A replay of the conference call will be available until Tuesday, August 4, 2020 at 11:59 PM Eastern Time (8:59 PM Pacific Time). Interested parties may access the replay of the conference call by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) using passcode 13706731. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website 30 minutes after the call concludes.

AboutExagen Inc.

Exagenis dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.Exagenhas developed and is commercializing a portfolio of innovative testing products under its AVISE brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagens goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis.

CONTACTS:

Investors

Westwicke Partners Mike CavanaughMike.Cavanaugh@westwicke.com 646.677.1838

Company Contact

Exagen Inc. Kamal Adawi, Chief Financial OfficerKAdawi@exagen.com 760.477.5514







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC